As Competitors Pursue Alternatives One Biotech Gains Prominence for its Potential to Treat Hepatitis

By Sharon di Stefano, Contributor Medgenics` (NYSEAMEX: MDGN) and (AIM: MEDU) (AIM: MEDG)  INFRADURE(TM) provides sustained production and delivery of interferon-alpha for the treatment of hepatitis. INFRADURE(TM) ...